摘要
目的：观察了解吉西他滨单药治疗老年晚期非小细胞肺癌（NSCLC）的临床疗效和毒性反应.方法：32例Ⅲ～Ⅳ期NSCLC患者均经病理组织学和（或）细胞学检查确诊.治疗剂量：国产吉西他滨（泽菲）1 000～1 250mg/m^2,静滴,第1、8天,每3～4周重复,2周期后CT评价疗效.结果：32例患者均可评价,获得CR 2例,PR 6例,有效率25.0%（8/32）.中位疾病进展时间（TTP）为5.7个月,中位生存期6.7个月,1年生存率28.1%.最主要的毒副反应为白细胞及血小板降低,但均可耐受.结论：吉西他滨单药治疗老年晚期NSCLC有较好疗效,可明显改善患者生存质量,延长生存时间,毒副反应轻,易于耐受.
Objective：To evaluate the clinical effect and toxicity of gemcitabine monotherapy in the treatment of elder advanced non-small cell lung cancer（NSCLC）. Methods：32 paients with advanced NSCLC diagnosed by pathology or cytology were enrolled into the study,The patients received GEM 1 000 - 1 2.50mg/m^2 on d1, d8, intravenously every 3-4 weeks and were evaluated effect after 2 cycles. Results：Complete remisson（CR） was observed in 2 cases and PR in 6 cases, the total response rate was 25.0% （8/32）. Mean time to progression（TIP） of all the patients was 5.7 months,median survival time was 6.7 months and 1 year survial rate was 28.1%. The main side effects were leucopenia and thrombocytopenia, but they were tolerable. Condusion：The regimen of gemcitabine is effective, safe and well-tolerable in the treatment of elder advanced NSCLC. It significantly improve the quality of life in patients with NSCLC, and prolong the survial time.
出处
《临床肿瘤学杂志》
CAS
2006年第3期190-192,共3页
Chinese Clinical Oncology
关键词
非小细胞肺癌
老年人
吉西他滨
化疗
Non-small cell lung cancer（NSCLC）
Elder patients
Gemcitabine
Chemotherapy
